The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Hodgkin lymphoma: A review and update on recent progress
Open accessAbstract
Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous Reed‐Sternberg cells in an inflammatory background. Patients are commonly diagnosed with HL in their 20s and 30s, and they present with supradiaphragmatic lymphadenopathy, often with systemic B symptoms. Even in advanced‐stage disease, HL is highly curable with combination chemotherapy, radiation, or combined‐modality treatment. Although the same doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk‐adapted approaches have helped de‐escalate therapy in low‐risk patients while intensifying treatment for higher risk patients. Even patients who are not cured with initial therapy can often be salvaged with alternate chemotherapy combinations, the novel antibody‐drug conjugate brentuximab, or high‐dose autologous or allogeneic hematopoietic stem cell transplantation. The programmed death‐1 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed/refractory HL. Alternate donor sources and reduced‐intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for more patients. Future research will look to integrate novel strategies into earlier lines of therapy to improve the HL cure rate and minimize long‐term treatment toxicities. CA Cancer J Clin 2018;68:116‐132 . © 2017 American Cancer Society .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,781
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., De Wolf- Peeters, C., Falini, B., & Gatter, K. (1994) · Blood · doi:10.1182/blood.v84.5.1361.1361 · Cited by 6,327
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,625
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
WHO Classification: Tumours of the Haematopoietic and Lymphoid Tissues (2008)
(2015) · Postgraduate Haematology · doi:10.1002/9781118853771.ch51 · Cited by 3,290
American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography
Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., Morris, E., Pisano, E., Schnall, M., Sener, S., et al. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.2.75 · Cited by 2,637
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001
Morton, L. M., Wang, S. S., Devesa, S. S., Hartge, P., Weisenburger, D. D., & Linet, M. S. (2006) · Blood · doi:10.1182/blood-2005-06-2508 · Cited by 1,683
Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P., Young, R. C., Rosenberg, S. A., Coltman, C. A., & Tubiana, M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1630 · Cited by 1,639
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease
DEVITA, V. T., SERPICK, A. A., & CARBONE, P. P. (1970) · Annals of Internal Medicine · doi:10.7326/0003-4819-73-6-881 · Cited by 1,436
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215
Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD
Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., Green, M. R., Gottlieb, A., & Peterson, B. A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211193272102 · Cited by 1,148
Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M., Haenel, M., Boissevain, F., Zschaber, R., Müller, P., Kirchner, H., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08938-9 · Cited by 1,140
Linch, D. C., Goldstone, A. H., McMillan, A., Chopra, R., Vaughan Hudson, G., Winfield, D., Hancock, B., Moir, D., & Milligan, D. (1993) · The Lancet · doi:10.1016/0140-6736(93)92411-l · Cited by 1,051
Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1316 · Cited by 989
Patel, P., Hanson, D. L., Sullivan, P. S., Novak, R. M., Moorman, A. C., Tong, T. C., Holmberg, S. D., Brooks, J. T., & for the Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators* (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-10-200805200-00005 · Cited by 942
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
Engert, A., Plütschow, A., Eich, H. T., Lohri, A., Dörken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K. C., Wilhelm, M., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000067 · Cited by 928
Younes, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J. M., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30167-x · Cited by 927
Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6525 · Cited by 846
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., d’Amore, F., Enblad, G., Franceschetto, A., Fulham, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510093 · Cited by 818
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 791
Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma
Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., Wimperis, J., Culligan, D., Popova, B., Smith, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408648 · Cited by 762
Report on the First International Workshop on interim-PET scan in lymphoma
Meignan, M., Gallamini, A., Meignan, M., Gallamini, A., & Haioun, C. (2009) · Leukemia & Lymphoma · doi:10.1080/10428190903040048 · Cited by 754
Late cardiotoxicity after treatment for Hodgkin lymphoma
Aleman, B. M. P., van den Belt-Dusebout, A. W., De Bruin, M. L., van 't Veer, M. B., Baaijens, M. H. A., Boer, J. P. D., Hart, A. A. M., Klokman, W. J., Kuenen, M. A., Ouwens, G. M., et al. (2007) · Blood · doi:10.1182/blood-2006-07-034405 · Cited by 746
Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60165-9 · Cited by 742
Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease
Aleman, B. M. P., van den Belt-Dusebout, A. W., Klokman, W. J., van’t Veer, M. B., Bartelink, H., & van Leeuwen, F. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.131 · Cited by 716
Green, M. R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 685
Toxicities of Immunotherapy for the Practitioner
Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0379 · Cited by 650
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
Schaapveld, M., Aleman, B. M. P., van Eggermond, A. M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M., Roesink, J., Raemaekers, J. M. M., de Boer, J. P., Zijlstra, J. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505949 · Cited by 637
Specht, L., Yahalom, J., Illidge, T., Berthelsen, A. K., Constine, L. S., Eich, H. T., Girinsky, T., Hoppe, R. T., Mauch, P., Mikhaeel, N. G., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.05.005 · Cited by 582
Thyroid Diseases after Treatment of Hodgkin's Disease
Hancock, S. L., Cox, R. S., & McDougall, I. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108293250902 · Cited by 579
Breast Cancer After Treatment of Hodgkin's Disease
Hancock, S. L., Tucker, M. A., & Hoppe, R. T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.1.25 · Cited by 536
Cheson, B. D., Ansell, S., Schwartz, L., Gordon, L. I., Advani, R., Jacene, H. A., Hoos, A., Barrington, S. F., & Armand, P. (2016) · Blood · doi:10.1182/blood-2016-05-718528 · Cited by 521
On Some Morbid Appearances of the Absorbent Glands and Spleen
Hodgkin (1832) · Journal of the Royal Society of Medicine · doi:10.1177/095952873201700106 · Cited by 516
Cardiac side-effects of cancer chemotherapy
Monsuez, J.-J., Charniot, J.-C., Vignat, N., & Artigou, J.-Y. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.03.003 · Cited by 467
van Nimwegen, F. A., Schaapveld, M., Cutter, D. J., Janus, C. P. M., Krol, A. D. G., Hauptmann, M., Kooijman, K., Roesink, J., van der Maazen, R., Darby, S. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4444 · Cited by 464
Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease
Fermé, C., Eghbali, H., Meerwaldt, J. H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., van't Veer, M. B., Walewski, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064601 · Cited by 450
Characteristics of Hodgkin's Lymphoma after Infectious Mononucleosis
Hjalgrim, H., Askling, J., Rostgaard, K., Hamilton-Dutoit, S., Frisch, M., Zhang, J.-S., Madsen, M., Rosdahl, N., Konradsen, H. B., Storm, H. H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023141 · Cited by 433
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
Viviani, S., Zinzani, P. L., Rambaldi, A., Brusamolino, E., Levis, A., Bonfante, V., Vitolo, U., Pulsoni, A., Liberati, A. M., Specchia, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100340 · Cited by 420
ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Wells, W. A., Winter, J. N., Horning, S. J., Dar, A. R., Shustik, C., Stewart, D. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111961 · Cited by 406
Managing Immune Checkpoint-Blocking Antibody Side Effects
Postow, M. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.76 · Cited by 403
PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
Yamamoto, R., Nishikori, M., Kitawaki, T., Sakai, T., Hishizawa, M., Tashima, M., Kondo, T., Ohmori, K., Kurata, M., Hayashi, T., et al. (2008) · Blood · doi:10.1182/blood-2007-05-085159 · Cited by 401
Chen, R., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Connors, J. M., Engert, A., Larsen, E. K., Huebner, D., et al. (2016) · Blood · doi:10.1182/blood-2016-02-699850 · Cited by 395
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 393
Raemaekers, J. M. M., André, M. P. E., Federico, M., Girinsky, T., Oumedaly, R., Brusamolino, E., Brice, P., Fermé, C., van der Maazen, R., Gotti, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.9298 · Cited by 387
Steidl, C., Connors, J. M., & Gascoyne, R. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8401 · Cited by 374
Diehl, V., Sextro, M., Franklin, J., Hansmann, M.-L., Harris, N., Jaffe, E., Poppema, S., Harris, M., Franssila, K., van Krieken, J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.776 · Cited by 360
Läubli, H., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 319
Sureda, A., Robinson, S., Canals, C., Carella, A. M., Boogaerts, M. A., Caballero, D., Hunter, A. E., Kanz, L., Slavin, S., Cornelissen, J. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2415 · Cited by 319
von Tresckow, B., Plütschow, A., Fuchs, M., Klimm, B., Markova, J., Lohri, A., Kral, Z., Greil, R., Topp, M. S., Meissner, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5807 · Cited by 314
Gordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Gospodarowicz, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4803 · Cited by 308
El-Galaly, T. C., d'Amore, F., Mylam, K. J., de Nully Brown, P., Bøgsted, M., Bukh, A., Specht, L., Loft, A., Iyer, V., Hjorthaug, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.4036 · Cited by 295
Burroughs, L. M., O'Donnell, P. V., Sandmaier, B. M., Storer, B. E., Luznik, L., Symons, H. J., Jones, R. J., Ambinder, R. F., Maris, M. B., Blume, K. G., et al. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.08.014 · Cited by 266
Self-citationHaverkos, B. M., Abbott, D., Hamadani, M., Armand, P., Flowers, M. E., Merryman, R., Kamdar, M., Kanate, A. S., Saad, A., Mehta, A., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761346 · Cited by 251
Merryman, R. W., Kim, H. T., Zinzani, P. L., Carlo-Stella, C., Ansell, S. M., Perales, M.-A., Avigdor, A., Halwani, A. S., Houot, R., Marchand, T., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738385 · Cited by 240
Herbaux, C., Gauthier, J., Brice, P., Drumez, E., Ysebaert, L., Doyen, H., Fornecker, L., Bouabdallah, K., Manson, G., Ghesquières, H., et al. (2017) · Blood · doi:10.1182/blood-2016-11-749556 · Cited by 216
Landgren, O., Engels, E. A., Pfeiffer, R. M., Gridley, G., Mellemkjær, L., Olsen, J. H., Kerstann, K. F., Wheeler, W., Hemminki, K., Linet, M. S., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj361 · Cited by 203
Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
Al-Mansour, M., Connors, J. M., Gascoyne, R. D., Skinnider, B., & Savage, K. J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9516 · Cited by 195
Mulder, R. L., Kremer, L. C. M., Hudson, M. M., Bhatia, S., Landier, W., Levitt, G., Constine, L. S., Wallace, W. H., van Leeuwen, F. E., Ronckers, C. M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70303-6 · Cited by 191
Decelerating growth and human breast cancer
Spratt, J. A., von Fournier, D., Spratt, J. S., & Weber, E. (1993) · Cancer · doi:10.1002/1097-0142(19930315)71:6<2062::aid-cncr2820710622>3.0.co;2-0 · Cited by 189
Behringer, K., Goergen, H., Hitz, F., Zijlstra, J. M., Greil, R., Markova, J., Sasse, S., Fuchs, M., Topp, M. S., Soekler, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61469-0 · Cited by 184
Long-Term Follow-up of Hodgkin's Disease Trial
Canellos, G. P., & Niedzwiecki, D. (2002) · New England Journal of Medicine · doi:10.1056/nejm200205023461821 · Cited by 138
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P. A., Bello, C. M., Benitez, C. M., Bernat, K., Bierman, P. J., Blum, K. A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0064 · Cited by 137
Self-citationvan der Kaaij, M. A. E., Heutte, N., Meijnders, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.1989 · Cited by 134
Lohri, A., Barnett, M., Fairey, R. N., O’Reilly, S., Phillips, G. L., Reece, D. E., Voss, N., & Connors, J. M. (1991) · Blood · doi:10.1182/blood.v77.10.2292.2292 · Cited by 132
Mauz‐Körholz, C., Gorde-Grosjean, S., Hasenclever, D., et al. (2007) · Cancer · doi:10.1002/cncr.22762 · Cited by 130
Sieniawski, M. K., Reineke, T., Nogová, L., Josting, A., Pfistner, B., Diehl, V., & Engert, A. (2007) · Blood · doi:10.1182/blood-2007-02-073544 · Cited by 128
Carde, P. P., Karrasch, M., Fortpied, C., Brice, P., Khaled, H. M., Casasnovas, O., Caillot, D., Gaillard, I., Bologna, S., Fermé, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5648 · Cited by 122
Advani, R. H., Horning, S. J., Hoppe, R. T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2069 · Cited by 112
Long‐term outcome after radiotherapy alone for lymphocyte‐predominant Hodgkin lymphoma
Wirth, A., Yuen, K., Barton, M. B., et al. (2005) · Cancer · doi:10.1002/cncr.21303 · Cited by 109
Merli, F., Luminari, S., Gobbi, P. G., Cascavilla, N., Mammi, C., Ilariucci, F., Stelitano, C. C., Musso, M., Baldini, L., Galimberti, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4817 · Cited by 107
Eichenauer, D. A., Plütschow, A., Fuchs, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4363 · Cited by 102
Semper, H., Muehlberg, F. L., Schulz‐Menger, J., Allewelt, M., & Grohé, C. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.025 · Cited by 100
Skoetz, N., Will, A., Monsef, I., Brillant, C., Engert, A., & von Tresckow, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007941.pub3 · Cited by 98
Rancea, M., Monsef, I., von Tresckow, B., Engert, A., & Skoetz, N. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009411.pub2 · Cited by 97
Fertility preservation after chemotherapy for Hodgkin lymphoma
van der Kaaij, M. A. E., van Echten‐Arends, J., Simons, A., & Kluin‐Nelemans, H. C. (2010) · Hematological Oncology · doi:10.1002/hon.939 · Cited by 93
Xing, K. H., Connors, J. M., Lai, A., Al-Mansour, M. M., Sehn, L. H., Villa, D. R., Klasa, R. J., Shenkier, T. N., Gascoyne, R. D., Skinnider, B., et al. (2014) · Blood · doi:10.1182/blood-2013-12-541078 · Cited by 88
Gibson, R., Delaune, J. D., Szady, A. D., & Markham, M. J. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-216228 · Cited by 85
Acute Myeloid Leukemia Following Hodgkin Lymphoma: A Population-Based Study of 35 511 Patients
Schonfeld, S. J., Gilbert, E. S., Dores, G. M., Lynch, C. F., Hodgson, D. C., Hall, P. N., Storm, H. H., Andersen, A., Pukkala, ., Holowaty, E. J., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj017 · Cited by 80
Appel, B. E., Chen, L., Buxton, A. B., Hutchison, R. E., Hodgson, D. C., Ehrlich, P. F., Constine, L. S., & Schwartz, C. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.3469 · Cited by 77
Risk of multiple primary malignancies following treatment of Hodgkin lymphoma
van Eggermond, A. M., Schaapveld, M., Lugtenburg, P. J., Krol, A. D. G., de Boer, J. P., Zijlstra, J. M., Raemaekers, J. M. M., Kremer, L. C. M., Roesink, J. M., Louwman, M. W. J., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532184 · Cited by 71
Hodgkin disease survival in Europe and the U.S.
Allemani, C., Sant, M., Angelis, R. D., Marcos‐Gragera, R., Coebergh, J. W. W., & and the EUROCARE Working Group (2006) · Cancer · doi:10.1002/cncr.21995 · Cited by 67
Cited by
The Global Landscape of EBV-Associated Tumors
Shannon-Lowe, C., & Rickinson, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00713 · Cited by 459
CCL5/CCR5 axis in human diseases and related treatments
Zeng, Z., Lan, T., Wei, Y., & Wei, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.004 · Cited by 378
Estimating the global burden of Epstein–Barr virus-related cancers
Wong, Y., Meehan, M. T., Burrows, S. R., Doolan, D. L., & Miles, J. J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03824-y · Cited by 314
microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis
Annese, T., Tamma, R., De Giorgis, M., & Ribatti, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581007 · Cited by 288
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Tian, Z., Liu, M., Zhang, Y., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01084-4 · Cited by 282
Metadata
- Authors
- Shanbhag, S., & Ambinder, R. F.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2017-12
- Volume
- 68
- Issue
- 2
- Pages
- 116-132
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W2774391334
- Cited by
- 481
- References
- 87
- FWCI
- 19.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.